“…The evolution of devices in serious cardiac rhythm pathology management has led progressively to the development of devices for the treatment of bradycardia, ventricular arrhythmia, and heart failure and for the prevention of sudden cardiac arrest leading to the delivery of pacemakers, implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT) plus ICD (CRT-D) and to the recent subcutaneous implantable cardioverter-defibrillator (S-ICD) [23][24][25]. Infectious complications leading also to endocarditis [1,8,[26][27][28][29][30][31][32][33] and non-infectious complications [9,21,23,[34][35][36][37] often necessitating removal [1,2,8,[37][38][39][40][41][42][43] affects patients wellbeing also leading to psychological difficulties increase [23,[44][45][46][47][48][49][50]. In addition, the improved patients' survival with the burden of concomitant diseases , the progressively younger implanted population and the increase in device and procedure complexity have raised the risk of system component structural failures .…”